Allena Pharmaceuticals, Inc. To Present Data On Lead Program ALLN-177 At American Society of Nephrology Kidney Week 2014

Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative non-systemic oral protein therapeutics to treat metabolic and orphan diseases, today announced that the company will present Phase 1 data on ALLN-177, its lead product for the treatment of hyperoxaluria, at the American Society of Nephrology (ASN) Kidney Week 2014, being held November 11-16, 2014 at the Pennsylvania Convention Center in Philadelphia.

Help employers find you! Check out all the jobs and post your resume.